Mersana Therapeutics Inc (MRSN)
2.725
+0.14
(+5.62%)
USD |
NASDAQ |
May 17, 16:00
2.725
0.00 (0.00%)
After-Hours: 20:00
Mersana Therapeutics Research and Development Expense (Quarterly): 18.69M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 18.69M |
| December 31, 2023 | 21.50M |
| September 30, 2023 | 30.53M |
| June 30, 2023 | 48.97M |
| March 31, 2023 | 47.28M |
| December 31, 2022 | 45.71M |
| September 30, 2022 | 50.64M |
| June 30, 2022 | 41.23M |
| March 31, 2022 | 35.81M |
| December 31, 2021 | 37.37M |
| September 30, 2021 | 35.28M |
| June 30, 2021 | 31.96M |
| March 31, 2021 | 27.42M |
| December 31, 2020 | 22.86M |
| September 30, 2020 | 16.55M |
| June 30, 2020 | 15.41M |
| March 31, 2020 | 12.22M |
| Date | Value |
|---|---|
| December 31, 2019 | 12.43M |
| September 30, 2019 | 13.70M |
| June 30, 2019 | 13.77M |
| March 31, 2019 | 15.14M |
| December 31, 2018 | 19.82M |
| September 30, 2018 | 15.18M |
| June 30, 2018 | 12.66M |
| March 31, 2018 | 12.26M |
| December 31, 2017 | 14.56M |
| September 30, 2017 | 11.41M |
| June 30, 2017 | 10.63M |
| March 31, 2017 | 10.11M |
| December 31, 2016 | 8.845M |
| September 30, 2016 | 7.555M |
| June 30, 2016 | 8.171M |
| March 31, 2016 | 7.436M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.22M
Minimum
Mar 2020
50.64M
Maximum
Sep 2022
28.96M
Average
28.97M
Median
Research and Development Expense (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 28.33M |
| Geron Corp | 29.37M |
| Insmed Inc | 121.08M |
| Altimmune Inc | 21.49M |
| InfuSystems Holdings Inc | -- |